Executive Changes Hit NuVasive Hard

Advances in medical science have had a dramatic impact on the quality of care that patients receive. In the area of spinal surgery, NuVasive (NASDAQ: NUVA) has made a lot of headway with its minimally disruptive medical devices, and consistent growth has rewarded shareholders who've had the patience to stick with the company over the long haul.

Coming into Thursday's second-quarter financial report, NuVasive investors were comfortable with their expectations for continued double-digit growth in revenue and earnings per share. NuVasive largely held up its end of the bargain on the financial front, but an announcement of a change in leadership and strategic vision going forward spooked shareholders and led to substantial share-price declines. Let's take a closer look at what just happened with NuVasive, and what it means for the future of the spinal-surgery specialist.

Image source: NuVasive.

Source: Fool.com